Evaluation of the eFfect of early Initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST)

Trial Profile

Evaluation of the eFfect of early Initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Secukinumab (Primary) ; Ciclosporin; Methotrexate
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Acronyms FIRST
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 31 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top